Could a Centuries-Old poison become a new weapon against a blood disorder?
NCT ID NCT06670222
First seen Aug 06, 2026 · Last updated Aug 07, 2026 · Updated 1 time
Summary
This early-stage trial is testing whether an oral form of arsenic trioxide can safely help people with low-risk myelodysplastic syndromes (MDS) who have not improved with standard treatments. The study will first find the safest dose, then check how well it works after several cycles. Participants are adults with low-risk MDS who have failed or are not eligible for other therapies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- oral arsenic trioxide (ATO)
- What this could lead to
- If it works, oral arsenic could offer a new treatment option for people with low-risk myelodysplastic syndromes who have not responded to standard therapies.
- What could go wrong
- This is an early-phase trial with a small number of participants, so the benefits are uncertain. Arsenic can be toxic, and the study is primarily checking safety and the right dose.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOW RISK MYELODYSPLASTIC SYNDROMES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU de Nice - Hôpital l'Archet - Service d'hématologie clinique
RECRUITINGNice, 06200, France
-
Hôpital Saint Louis - Service Hématologie séniors
RECRUITINGParis, 75010, France
-
Institut Gustave Roussy - Service d'hématologie
RECRUITINGVillejuif, 94805, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.